Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADVM NASDAQ:DTIL NASDAQ:EQ NASDAQ:KLTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$2.32-2.9%$2.49$1.78▼$8.56$49.93M0.77117,764 shs79,688 shsDTILPrecision BioSciences$4.62-2.7%$4.75$3.61▼$11.09$52.67M1.52216,125 shs61,917 shsEQEquillium$0.71+81.6%$0.37$0.27▼$1.50$13.97M1.15576,012 shs143.57 million shsKLTOKlotho Neurosciences$0.92-4.6%$1.09$0.11▼$3.91$44.39M10.925.91 million shs854,429 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-2.93%-14.07%+2.65%-33.52%-68.73%DTILPrecision BioSciences-2.74%-10.29%+8.45%-19.65%-51.52%EQEquillium+81.59%+76.31%+122.92%+69.05%-4.98%KLTOKlotho Neurosciences-4.55%-25.21%-22.70%+426.26%+91,989,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies4.2764 of 5 stars3.44.00.04.82.21.70.6DTILPrecision BioSciences4.0888 of 5 stars3.53.00.04.60.61.71.3EQEquillium1.814 of 5 stars3.24.00.00.00.61.70.0KLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies 2.80Moderate Buy$23.80925.86% UpsideDTILPrecision BioSciences 3.00Buy$47.00917.32% UpsideEQEquillium 2.33Hold$3.00322.54% UpsideKLTOKlotho Neurosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EQ, DTIL, KLTO, and ADVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $12.005/21/2025DTILPrecision BioSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.005/15/2025ADVMAdverum BiotechnologiesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$5.00 ➝ $4.005/15/2025ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.005/15/2025ADVMAdverum BiotechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$1M48.46N/AN/A$3.40 per share0.68DTILPrecision BioSciences$68.70M0.75N/AN/A$6.87 per share0.67EQEquillium$41.10M0.62N/AN/A$0.54 per share1.31KLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$130.93M-$6.40N/AN/AN/AN/A-130.53%-66.31%8/11/2025 (Estimated)DTILPrecision BioSciences$7.17M-$2.01N/AN/AN/A-42.99%-69.26%-29.30%8/7/2025 (Estimated)EQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)KLTOKlotho Neurosciences-$6.15M-$0.36N/A∞N/AN/A-1,779.01%-275.01%8/18/2025 (Estimated)Latest EQ, DTIL, KLTO, and ADVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EQEquillium-$0.1850N/AN/AN/AN/AN/A8/11/2025Q2 2025ADVMAdverum Biotechnologies-$2.24N/AN/AN/AN/AN/A8/7/2025Q2 2025DTILPrecision BioSciences-$0.09N/AN/AN/A$6.27 millionN/A5/15/2025Q1 2025DTILPrecision BioSciences-$0.43-$2.21-$1.78-$2.21$5.00 million$0.03 million5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A3.573.57DTILPrecision BioSciences0.456.626.62EQEquilliumN/A2.702.70KLTOKlotho NeurosciencesN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%DTILPrecision BioSciences37.99%EQEquillium27.05%KLTOKlotho Neurosciences20.07%Insider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies6.00%DTILPrecision BioSciences4.50%EQEquillium31.60%KLTOKlotho Neurosciences26.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies19020.89 million19.64 millionOptionableDTILPrecision BioSciences20011.09 million10.59 millionNo DataEQEquillium4035.72 million24.43 millionNot OptionableKLTOKlotho NeurosciencesN/A46.05 million33.76 millionN/AEQ, DTIL, KLTO, and ADVM HeadlinesRecent News About These CompaniesUPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology | KLTO ...July 25, 2025 | gurufocus.comUPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyJuly 25, 2025 | prnewswire.comKlotho Neurosciences, Inc. to Expand Development Programs Beyond NeurologyJuly 24, 2025 | prnewswire.comKlotho Neurosciences, Inc. Partners with AAVnerGene Inc. to Make Klotho's Gene Therapy AssetsJuly 22, 2025 | prnewswire.comKlotho Neurosciences regains full compliance with Nasdaq listing standardsJuly 16, 2025 | msn.comKlotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum Closing Bid Price and Stockholder Equity RulesJuly 16, 2025 | prnewswire.comNew UAB-developed gene therapy for ALS receives orphan drug designationJuly 15, 2025 | news-medical.netNALS gene therapy candidate KLTO‑202 wins orphan drug statusJuly 15, 2025 | alsnewstoday.comAUS FDA grants orphan drug designation to Klotho Neurosciences’ KLTO-202 to treat amyotrophic lateral sclerosisJuly 12, 2025 | pharmabiz.comPKlotho Neurosciences stock soars after FDA grants orphan drug status ...July 11, 2025 | uk.investing.comKLTO: Klotho Neurosciences, Inc. Common Stock Stock Price, Quote ...July 11, 2025 | fxempire.comFKlotho Neurosciences Shares Jump as FDA Grants Orphan Drug Status for ALS TherapyJuly 10, 2025 | msn.comKlotho Neurosciences stock soars after FDA grants orphan drug status for ALSJuly 10, 2025 | ca.investing.comKlotho Neurosciences' ALS therapy awarded FDA Orphan Drug DesignationJuly 10, 2025 | proactiveinvestors.comKlotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")July 10, 2025 | prnewswire.comKLTO - Klotho Neurosciences Inc Chart - MorningstarJuly 2, 2025 | morningstar.comMKlotho Neurosciences Begins Manufacturing Gene Therapy for ALSJuly 2, 2025 | theglobeandmail.comKlotho Neurosciences moves forward with manufacturing gene therapy to treat amyotrophic lateral sclerosisJuly 1, 2025 | pharmabiz.comPKlotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALSJune 30, 2025 | prnewswire.comKlotho Neurosciences, Inc. and the Okinawa Research Center for Longevity Science, Leading Experts on the Okinawa "Blue Zone", Announce a Plan to Study Tissue Levels of the Human Klotho Gene and Protein in the World's Longest-Lived PopulationJune 24, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendAI Chip Arms Race: 3 Must-Watch Equipment StocksBy Chris Markoch | July 10, 2025View AI Chip Arms Race: 3 Must-Watch Equipment StocksShield Your Portfolio From Aug. 1 Tariffs With This Low-Vol ETFBy Jordan Chussler | July 15, 2025View Shield Your Portfolio From Aug. 1 Tariffs With This Low-Vol ETFAES Gains 20% as Private Equity Eyes AI Hyperscale Energy PlayerBy Leo Miller | July 14, 2025View AES Gains 20% as Private Equity Eyes AI Hyperscale Energy PlayerCorrection Equals Opportunity in Domino’s Pizza StockBy Gabriel Osorio-Mazilli | July 6, 2025View Correction Equals Opportunity in Domino’s Pizza StockEQ, DTIL, KLTO, and ADVM Company DescriptionsAdverum Biotechnologies NASDAQ:ADVM$2.32 -0.07 (-2.93%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.32 0.00 (0.00%) As of 08/1/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.Precision BioSciences NASDAQ:DTIL$4.62 -0.13 (-2.74%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.62 +0.00 (+0.11%) As of 08/1/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Equillium NASDAQ:EQ$0.71 +0.32 (+81.59%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.57 -0.14 (-19.01%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Klotho Neurosciences NASDAQ:KLTO$0.92 -0.04 (-4.55%) As of 08/1/2025 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
